Study to Evaluate Blood Cell Lines From Patients With Gaucher Disease

Status Completed

Clinical Trial Summary

The purpose of this study is to learn more about Gaucher disease. The information we collect from medical histories and a blood sample from people with Gaucher disease may help us pinpoint certain things that are different between people who have Gaucher disease and people who do not have Gaucher disease. This information may be useful in the future to help find new treatments for Gaucher disease.

Clinical Trial Description

This study is designed to evaluate the ex vivo response to pharmacological chaperone therapy by testing blood samples from previously treated and untreated patients with Gaucher disease. The study will include patients with non-neuropathic Gaucher disease (type I) and neuropathic Gaucher disease (types II and/or III).

All subjects will participate in one study visit. Clinical information will be collected retrospectively from medical records. Information collected will include Gaucher disease diagnosis and history, medical history, family history, assessments of clinical severity, and genotype. A blood sample will be collected and various cells will be isolated for laboratory testing and research. ;

Study Design

N/A

Related Conditions & MeSH terms

Gaucher Disease

Clinical Trial Details

NCT number	NCT00351156
Study type	Observational
Source	Amicus Therapeutics
Contact
Status	Completed
Phase	N/A
Start date	July 2006
Completion date	March 2007

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04189601` - Complement Activation in the Lysosomal Storage Disorders
Completed	`NCT04430881` - A National Study in Patients With Unexplained Splenomegaly
Completed	`NCT02536911` - A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate	Phase 1
Completed	`NCT02536937` - A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate	Phase 1
Completed	`NCT01411228` - A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease	Phase 3
Terminated	`NCT04094181` - A Study of VPRIV in Participants With Gaucher Disease Previously Treated With Other Enzyme Replacement Therapies or Substrate Reduction Therapies
Completed	`NCT00391625` - Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)	Phase 1/Phase 2
Completed	`NCT03625882` - Survey Study for Velaglucerase Alfa (VPRIV) in Japan
Active, not recruiting	`NCT05526664` - Omics Gaucher Study: Multiomic Approach
Completed	`NCT02536755` - Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies	Phase 3
Recruiting	`NCT01344096` - Thrombocytopathy in Gaucher Disease Patients	N/A
Completed	`NCT01881633` - A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers	Phase 1
Recruiting	`NCT06116071` - Biomarkers Related to Bone in Pediatric Gaucher Disease
Recruiting	`NCT01951989` - Intra-monocyte Imiglucerase Kinetics in Gaucher Disease	Phase 2
Completed	`NCT00258778` - Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)	Phase 1
Recruiting	`NCT04388969` - World Data on Ambroxol for Patients With GD and GBA Related PD
Recruiting	`NCT05992532` - GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma
Terminated	`NCT04145037` - Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease	Phase 1/Phase 2
Completed	`NCT00302146` - Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations
Active, not recruiting	`NCT02605603` - SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease